Literature DB >> 26902634

Are We Sure that Blood Transfusion is Associated with Recurrence of Hepatocellular Carcinoma After Hepatectomy?

Han-Yue Mo1, Xue-Mei You1, Bang-De Xiang1, Le-Qun Li1, Jian-Hong Zhong2.   

Abstract

Entities:  

Mesh:

Year:  2016        PMID: 26902634     DOI: 10.1007/s00268-016-3464-7

Source DB:  PubMed          Journal:  World J Surg        ISSN: 0364-2313            Impact factor:   3.352


× No keyword cloud information.
  5 in total

1.  Blood transfusion is associated with recurrence of hepatocellular carcinoma after hepatectomy in Child-Pugh class A patients.

Authors:  Noboru Harada; Ken Shirabe; Takashi Maeda; Hiroto Kayashima; Teruyoshi Ishida; Yoshihiko Maehara
Journal:  World J Surg       Date:  2015-04       Impact factor: 3.352

2.  Intraoperative allogeneic red blood cell transfusion in ampullary cancer outcome after curative pancreatoduodenectomy: a clinical study and meta-analysis.

Authors:  Hou Shan Yao; Qiang Wang; Wei Jun Wang; Zhi Qian Hu
Journal:  World J Surg       Date:  2008-09       Impact factor: 3.352

3.  Does the preoperative alpha-fetoprotein predict the recurrence and mortality after hepatectomy for hepatocellular carcinoma without macrovascular invasion in patients with normal liver function?

Authors:  Atsushi Kudo; Satoshi Matsumura; Daisuke Ban; Takumi Irie; Takanori Ochiai; Shinji Tanaka; Shigeki Arii; Minoru Tanabe
Journal:  Hepatol Res       Date:  2014-05-06       Impact factor: 4.288

Review 4.  Effects of allogeneic red blood cell transfusions on clinical outcomes in patients undergoing colorectal cancer surgery: a systematic review and meta-analysis.

Authors:  Austin G Acheson; Matthew J Brookes; Donat R Spahn
Journal:  Ann Surg       Date:  2012-08       Impact factor: 12.969

5.  Perioperative allogenenic blood transfusion is associated with worse clinical outcomes for hepatocellular carcinoma: a meta-analysis.

Authors:  Lei Liu; Zhiwei Wang; Songqi Jiang; Bingfeng Shao; Jibing Liu; Suqing Zhang; Yilong Zhou; Yuan Zhou; Yixin Zhang
Journal:  PLoS One       Date:  2013-05-31       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.